Biotech company Imperagen announced on Thursday a £5 million ($6.7 million) seed round led by PXN Ventures, with participation from IQ Capital and Northern Gritstone.
Advances in AI, particularly quantum physics applications, are enabling new breakthroughs in biotechnology, attracting significant venture capital investment.
This investment highlights the increasing confluence of quantum computing, AI, and biotech, pointing towards a future where computational power accelerates biological engineering.
The funding enables Imperagen to further develop its enzyme engineering platform, potentially leading to more efficient and novel biological solutions across various industries.
- · Imperagen
- · Synthetic Biology sector
- · AI-driven drug discovery platforms
- · Venture Capital firms with biotech focus
- · Traditional enzyme engineering methods
- · Biotech companies lacking advanced computational capabilities
Funds Imperagen's research and development in AI-driven enzyme engineering.
Accelerates the development of new industrial enzymes and therapeutic proteins.
Establishes 'quantum biotech' as a distinct, high-growth area within synthetic biology.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at TechCrunch — Venture